From USD 79.6 Billion to USD 161.3 Billion: The Customer Relationship Management Market's Seven-Year Sprint

Customer expectations keep rising, and CRM platforms have moved from sales databases to AI-driven engines for personalization, service, and retention. According to Grand View Research, the global customer relationship management market was valued at USD 79.6 billion in 2025. It is projected to reach USD 86.4 billion in 2026 and USD 161.3 billion by 2033, a CAGR of 9.3% from 2026 to 2033.

Core Market Snapshot

• By solution: Customer service led in 2025 with a 22.5% revenue share. Social media monitoring is expected to be the fastest-growing application, at a 17.2% CAGR.
• By deployment: Cloud accounted for 59.4% of revenue in 2025. On-premise remains relevant for organizations with strict data privacy needs.
• By enterprise size: Large enterprises held a 59.2% share, while SMEs are projected to grow fastest, at a 16.2% CAGR.
• By end use: BFSI led with a 22.2% share. IT & telecom is expected to grow at a 16.3% CAGR.

North America led the market with a 40.4% revenue share in 2025, reflecting the concentration of major CRM vendors in the region. These vendors keep investing in AI, automation, analytics, and industry-specific solutions. The U.S. is the largest national market. Asia Pacific is the fastest-growing region, at a projected 16.3% CAGR.

Top Vendors and Market Share

The CRM landscape has two tiers: global platform leaders and agile challengers.

Established players. Grand View Research names Salesforce, Microsoft, SAP, Oracle, and Adobe among the leading vendors, and lists HubSpot with this group in its benchmarking. They compete on:

• Broad portfolios spanning sales, marketing, service, and commerce
• Heavy investment in AI, customer data platforms (CDPs), and analytics
• Large partner ecosystems and global customer bases
• Acquisitions and cloud infrastructure expansion

Their trade-offs are higher implementation and subscription costs, longer onboarding, and integration complexity for smaller organizations.

Emerging players. Zoho, Creatio, Freshworks, SugarCRM, and Insightly target SMEs and the mid-market. They compete on:

• Cloud-native, user-friendly products
• Faster deployment and flexible pricing
• Low-code and no-code customization
• Responsiveness to niche and regional needs

Their limitations are a smaller customer base, lower brand visibility, and tighter R&D budgets than the giants.

The full list of companies profiled in the report also includes ClickUp, Copper CRM, monday.com, Nimble, and Zendesk. The public report summary does not publish vendor-level market share percentages, so the full report is where you will find company share and competitive positioning in detail.

Get a Closer Look at the Data Explore market estimates, trend analyses, and forecasts before you buy. Download Free Sample Report

Emerging Drivers & Trends

1. Generative and agentic AI are now table stakes. Vendors are racing to embed AI agents directly into CRM workflows:

• Microsoft announced its Dynamics 365 2026 release wave 1 in March 2026, adding AI capabilities across Sales, Customer Service, Contact Center, and Customer Insights.
• Adobe introduced Adobe CX Enterprise in April 2026, an agentic AI solution spanning acquisition, conversion, and loyalty.
• Freshworks launched Freddy AI Agent Studio and an MCP Gateway in May 2026, so organizations can build custom AI agents and connect them to enterprise apps.
• Insightly introduced CRM Copilot in December 2025 to analyze pipeline data and automate tasks.

2. Social media becomes a service channel. Customers expect instant responses on social platforms. CRM-integrated monitoring helps brands track mentions and sentiment and resolve issues proactively, which explains the segment's 17.2% projected CAGR.
3. Mobile CRM. Especially in the U.S., sales, retail, and field-service teams increasingly rely on mobile CRM to update records and respond to customers in real time.
4. SaaS opens the door for SMEs. Budget-constrained small businesses can adopt cloud-based CRM without heavy infrastructure spending, which supports the segment's fast projected growth.

Market Drivers & Ecosystem Trends

Driver: demand for personalized, customer-centric experiences. Organizations want a unified view of customer interactions, preferences, and purchase history. CRM platforms automate sales and marketing, personalize communications, and improve retention. Combined with AI-powered analytics, omnichannel tools, and CDPs, this is accelerating adoption across industries.

Restraint: implementation and maintenance costs. Licensing, customization, data migration, ERP and marketing-tool integration, training, and security add up. These costs can delay purchasing decisions, particularly for SMEs that need a clear ROI.

Opportunity: AI, automation, and omnichannel engagement. Predictive forecasting, intelligent lead scoring, sentiment analysis, and automated service are creating room for unified platforms that combine sales, marketing, support, analytics, and customer data management.

Regional ecosystem momentum

• Asia Pacific: E-commerce expansion, a growing SME base, and government digital initiatives are fueling demand in China and India. Both are cited as key growth contributors.
• Europe: Digitalization, regulatory requirements, and local vendor and cloud investments (such as Oracle's second cloud region in France) support growth.
• Middle East & Africa: Retail and electronics brands entering the region and rapidly growing SMEs, especially in Saudi Arabia, Turkey, and Egypt, are driving adoption.

What This Means for Stakeholders

• Vendors: AI agents, CDP integration, and SME-friendly packaging are the clearest differentiators.
• Enterprise buyers: Weigh the total cost of ownership and integration complexity, not just features.
• SMEs: Cloud CRM lowers the barrier to entry, and mobile and social features are increasingly expected.
• Investors: Asia Pacific, SMEs, and social media monitoring show the strongest projected growth rates.

Need Insights Tailored to Your Strategy? Add regions, segments, or competitor detail with 20% free customization. Customize This Report

Paws, Claws, and Profit Margins: Inside the Pet Food Market

The global pet food market was valued at USD 128.7 billion in 2025. Grand View Research projects it will reach USD 135 billion in 2026 and USD 191.2 billion by 2033, a CAGR of 5.1%. Pet adoption and rising concern for pet health and wellness are driving that growth. In the U.S. alone, 71% of households owned a pet in 2025, with dogs in 51% of homes and cats in 37%.

This post covers how the market breaks down, the trends shaping it, and how the competition is positioned.

Core Market Segmentation

The report segments the market by product, pet type, category, distribution channel, and region.

By product. Dry pet food led in 2025 with a 59.1% revenue share. It has a long shelf life, is easy to handle, costs less than wet or fresh options, and is sold almost everywhere. Snacks and treats are the fastest-growing product segment at a 5.4% CAGR. Owners use treats for training and bonding, and functional versions for dental care, joint support, and digestion are gaining traction.

By pet type. Dogs accounted for 60.8% of revenue in 2025, helped by their popularity as companions and growing interest in premium, functional diets. Cats are growing at a 4.7% CAGR through 2033 as cat ownership rises and owners look for feline-specific nutrition.

By category. Traditional pet food held 86.2% of revenue, supported by affordability, brand familiarity, and mass-retail reach. Specialist veterinary nutrition is growing at 5.2% annually. More chronic conditions are being diagnosed in pets, including obesity, renal disorders, food sensitivities, and gastrointestinal issues, and vet recommendations build owner confidence in clinical diets.

By distribution channel. Pet specialty stores led with 28.5% of revenue, because knowledgeable staff can advise on special diets such as grain-free, hypoallergenic, and senior formulas. E-commerce is the fastest-growing channel at a 6.6% CAGR, driven by home delivery, subscriptions, and bulk-order perks.

By region. North America held 41.4% of revenue in 2025 on high ownership rates, premium spending, and mature retail channels. Asia Pacific is the fastest-growing region at a 6.8% CAGR, led by China, which accounted for 34.3% of regional revenue. Central & South America (6.3% CAGR) and the Middle East & Africa (5.6% CAGR) are also expanding on urbanization and modern retail growth.

Defining Industry Trends

1. Pet humanization is pushing owners toward premium. Owners increasingly treat pets as family. They read ingredient lists, check protein sources, and look for functional ingredients such as probiotics, prebiotics, antioxidants, and vitamins.
2. Nutrition is becoming preventive health care. Concerns like obesity, joint health, and digestive wellness are moving food choices beyond basic feeding. Osteoarthritis alone is reported to affect over half of dogs and cats globally.
3. Personalization is the biggest opportunity. Demand is growing for formulations tailored to breed, size, age, and life stage, such as puppy, kitten, and senior diets, plus mobility and oral health. Supplement-style purchases are heavily influenced by the product's health-benefit claim, so targeted functionality sells.
4. Convenience and online buying are reshaping habits. Portion-controlled and single-serve formats, subscriptions, and wider online selection all make feeding easier. Retailers like Zooplus and Bitiba show how strong online pet food retail has become in Europe.
5. Price sensitivity is the main headwind. In July 2025, 42% of pet owners called high pet food prices a significant challenge, rising to 45-46% in lower-income households. Premium brands face pressure from value-oriented and private-label alternatives.
6. Clean labels and sustainability matter more. In Europe, brands are leaning into transparent, human-grade ingredients and free-from claims, mirroring clean-eating trends in human food.

Want to see the full market estimates, forecasts, and company insights? Download Free Sample

Competitive Landscape

The market is moderately consolidated. Multinationals compete alongside regional and specialized players, and most are investing in R&D, new recipes, marketing, and M&A.

Established players include The J.M. Smucker Company, Nestlé Purina, Mars, Incorporated, Hill's Pet Nutrition, and General Mills. They expand across dry, wet, snacks, and specialized nutrition. Their advantages are brand recognition, scale, and broad distribution. Their weaknesses are high operating costs, complex supply chains, exposure to ingredient and packaging price swings, and pressure from private labels.

Emerging players include LUPUS Alimentos, Total Alimentos, WellPet LLC, The Hartz Mountain Corporation, and Simmons Foods. They focus on specialized and value-oriented products, private-label manufacturing, and regional expansion. They can develop products quickly and know their regions well, but they have a smaller global footprint and fewer financial resources.

Recent moves worth noting:

• In June 2025, General Mills extended its Blue Buffalo brand into a fresh, minimally processed pet food line.
• In 2024, Nestlé Purina commissioned a 1.3-million-sq-ft manufacturing plant in North Carolina to add capacity and improve efficiency and sustainability.

The Bottom Line

Pet food is growing steadily, with the biggest openings in functional and life-stage nutrition, veterinary diets, treats, e-commerce, and Asia Pacific. Winners will balance premium innovation against affordability.

Have questions about the data or need market insights tailored to your strategy? Speak to Analyst

Beyond the Brackets: How the Clear Aligners Market Is Rewriting Orthodontics

Straight teeth used to mean metal brackets and wires. Today a growing share of patients choose a series of nearly invisible, removable trays. According to Grand View Research, the clear aligners market is on track for one of the fastest growth runs in medical devices.

Market Overview & Key Stats

The clear aligners market has moved from a niche cosmetic option to a core part of modern orthodontic care. Demand is rising on several fronts at once. Adults want discreet, convenient treatment that fits around work and social life. Dentists and orthodontists are adopting digital workflows such as intraoral scanning, AI-assisted planning and in-house production. New entrants and established dental companies keep widening the range of cases aligners can treat. Together, these forces are pushing the market into a sustained, double-digit growth phase, with North America leading in revenue today and Asia Pacific set to expand fastest as dental infrastructure and incomes grow.

Snapshot of the numbers:

• Market size, 2025: USD 5.5 billion
• Estimated size, 2026: USD 6.6 billion
• Forecast, 2033: USD 17.9 billion
• CAGR (2026–2033): 15.2%
• North America's revenue share (2025): 50.0%
• Fastest-growing region: Asia Pacific

What's driving demand?

• Adult orthodontics is booming. Adults increasingly value aesthetics, comfort and discretion, and they are moving away from fixed braces.
• There is a large untreated population. A systematic review of 47 studies found malocclusion in about 54% of preschool-aged children worldwide. That is a long pipeline of future teen and adult patients.
• Dental disease carries a large economic burden. A 2024 estimate put the global cost of dental diseases at USD 710 billion, reflecting a large pool of people needing treatment.
• Consumer behavior has shifted. Patients cite discreet appearance, removability, easier hygiene and comfort. Social media, dentist recommendations, financing options and direct-to-consumer models are speeding adoption.

Aligners are not a perfect fit for every case, though. Clinical reviews note that predictability varies with the type of tooth movement required.

Who's shaping the market

The competitive field spans orthodontic giants, dental distributors and fast-growing regional brands. Key players include:

• Align Technology
• Envista (Ormco Corporation)
• Institut Straumann AG
• 3M / Solventum
• Dentsply Sirona
• Henry Schein
• Angel Aligner
• Shanghai Smartee Denti-Technology
• SCHEU-DENTAL, Great Lakes Dental Technologies, DynaFlex and Modern Me GmbH

These companies compete on digital innovation, materials science and clinical partnerships. The sector also sees moderate-to-high merger and partnership activity, as companies combine software, intraoral scanning and materials expertise into integrated digital ecosystems.

Want to see the data first? Explore market estimates, trend analyses and forecasts in the free sample. Download Free Sample

The technologies changing treatment

1. Artificial intelligence. A 2025 scoping review of 41 clinical studies found AI is now used for automated tooth segmentation (with accuracy approaching 98%), merging CBCT and intraoral scan data, predicting outcomes and remotely monitoring progress. Other research suggests AI can reduce labor and material costs and speed up production.
2. Direct 3D printing. The industry is moving from thermoformed trays to directly printed aligners. Printing offers greater precision, customization, speed and less waste, though material safety, long-term performance and industry standards remain open challenges.
3. Recent launches show the pace of change:

• March 2025: LuxCreo introduced the 4D Aligner, described as the first MDR/CE Class IIa-certified directly 3D-printed aligner, enabling same-day production.
• September 2025: Medit launched Medit Aligners, integrated with its orthodontic suite for chairside, same-day starts.
• September 2025: Ormco introduced Spark Junior, a two-phase system for children and teens.
• July 2025: Align Technology launched an aligner with integrated occlusal blocks for mandibular advancement in growing patients.
• November 2024: Solventum launched the first 3D-printed aligner attachments.
• September 2024: OrthoFX launched NiTime in India, requiring just 9–12 hours of daily wear versus roughly 22 for conventional aligners.

The research pipeline is also broad. Ongoing trials cover skeletal open bite, Class II correction, accelerated tooth movement and direct-printed versus thermoformed aligners.

Core Market Segments & Demographics

By age

Adults led with a 65.1% share in 2025, driven by untreated malocclusion and rising aesthetic awareness. Teens are the fastest-growing segment. A 2025 meta-analysis of adolescent interceptive treatment reported arch expansion of about 3.0–3.5 mm and patient and parent satisfaction of 85–92%.

By material

Polyurethane held 67.7% of the market in 2025, valued for flexibility, transparency and consistent force delivery. PETG is expected to grow significantly, thanks to its clarity, stain resistance and cost-effectiveness for value-tier brands.

By end use

Standalone practices led in 2025, helped by dentists shifting toward private, higher-margin elective care. In the UK, strained NHS dentistry is accelerating that shift. Group practices are forecast to grow fastest, thanks to centralized planning, digital infrastructure and multi-location patient acquisition.

By distribution channel

Offline channels held 86.0% of revenue as clinics expand into tier-2 and tier-3 cities. Online is the fastest-growing channel, powered by virtual consultations, AI-based planning and home impression kits. Complex cases still keep hybrid care dominant.

By region

• North America (50.0% share): advanced dental infrastructure, early adoption of intraoral scanners and high disposable income. The U.S. is the largest country market.
• Europe: steady growth, with private practices and 3D printing on the rise.
• Asia Pacific: the fastest growth through 2033. China is both a large market and a manufacturing hub. India's market is expanding on rising awareness and digital dentistry adoption, though malocclusion studies there vary widely by region and method.
• Latin America and MEA: moderate growth, with Brazil, Mexico, the UAE and Saudi Arabia emerging, tempered by cost sensitivity and specialist shortages.

The Bottom Line

With AI-driven planning, 3D-printed aligners, a growing adult and teen patient base and fast-growing emerging markets, clear aligners are becoming a mainstream orthodontic standard. Manufacturers, clinics, investors and suppliers all have good reasons to understand where this market is headed.

Need insights tailored to your strategy? Add the regions, segments or competitor details that matter to your business, with 20% free customization. Customize This Report

The Medical Imaging Market Is Getting a Brain Transplant, and It's AI

Medical imaging sits at the center of modern diagnosis. From spotting a fracture to planning a tumor resection, clinicians depend on imaging at almost every stage of care. According to Grand View Research, the medical imaging market is entering a steady growth phase, driven by an aging population, rising chronic disease, and a wave of AI-enabled equipment.

Key Technologies and Modalities

The market spans five major technology groups:

• X-ray devices: radiography, fluoroscopy, and mammography.
• Ultrasound: handheld, compact, and cart/trolley-based systems.
• Computed tomography (CT): high-, mid-, and low-end slice systems, plus cone beam CT.
• Magnetic resonance imaging (MRI): closed and open systems.
• Nuclear imaging: SPECT and PET.

MRI led the market in 2025 with a 27.9% revenue share. It is widely used for the brain, spine, heart, breast, abdomen, and musculoskeletal structures. Advances such as diffusion tensor imaging, perfusion imaging, functional MRI, and intraoperative MRI keep widening its clinical use. Deep learning is also speeding up scans. GE HealthCare's FDA-cleared Sonic DL is one example, enabling high-quality cardiac imaging within a single heartbeat.

CT is the fastest-growing modality. It delivers high-resolution views of organs, tissue, and bone, and newer systems are faster, more accurate, and safer. Cardiac CT is gaining particular momentum, helped by guideline support for coronary CT angiography in evaluating chest pain.

By application, orthopedic imaging held the largest share (32.4%) in 2025, supported by rising bone injuries and road accident trauma. Cardiology is projected to grow fastest.

Want deeper insights? The full Grand View Research report covers 20+ countries, segment-level forecasts, and competitive profiles. Download Free Sample to explore the data and report structure.

Major Growth Drivers

1. An aging global population. Older adults face higher risks of heart disease, stroke, cancer, and osteoporosis, all of which rely on imaging. The UN expects the number of people aged 65 and above to double over the next 30 years, reaching 1.6 billion by 2050.
2. Rising chronic disease burden. In the U.S. alone, an estimated 1.96 million new cancer cases were projected for 2023. The WHO reports roughly 3.6 billion diagnostic tests performed worldwide each year. Surgeons also increasingly rely on preoperative MRI and CT to map tumor margins.
3. Demand for early, accurate diagnosis. Imaging is non-invasive and often preferred over alternatives such as biopsies and blood tests, which gives it a durable advantage.
4. Sustained R&D and investment. Public and private funding is pouring into next-generation systems, from Canon's in-house-built Vantage Galan 3T MRI to United Imaging's USD 490 million R&D and manufacturing campus in Shanghai.

A note on restraints: high equipment cost remains a barrier, particularly in low- and middle-income countries. Providers are responding by evaluating total cost of ownership rather than sticker price alone.

Market Overview & Core Numbers

• Market size, 2025: USD 43.5 billion
• Estimated market size, 2026: USD 45.5 billion
• Projected market size, 2033: USD 64.7 billion
• CAGR, 2026–2033: 5.1%
• Largest region (2025): North America, 36.3% share
• Fastest-growing region: Asia Pacific
• Leading technology: MRI, 27.9% share
• Leading application: Orthopedics, 32.4% share
• Leading end-use: Hospitals, 42.0% share

Regional picture: North America leads thanks to high healthcare spending, strong reimbursement, and heavy chronic disease incidence, and it is expected to keep that position. Asia Pacific should grow fastest, fueled by population growth, expanding R&D, and demand for both conventional and advanced systems. In India, for instance, Philips has expanded its manufacturing and R&D facility in Maharashtra.

End-use picture: Hospitals dominate because they invest heavily in advanced imaging. Diagnostic imaging centers are growing at the highest rate, driven by greater awareness of cancer and neurological conditions and rising CT and MRI volumes.

Dominant Market Trends

AI is becoming the core of the imaging workflow. AI algorithms analyze complex images faster, support early detection, and ease radiologist workload. GE HealthCare's work with Mass General Brigham on foundation models, and its SonoSAMTrack model for ultrasound segmentation, show where the industry is heading. Its acquisition of Caption Health also added AI-guided ultrasound.

Portable and point-of-care imaging is moving care beyond the hospital. Examples include Siemens Healthineers' mobile 1.5T MAGNETOM Viato.Mobile MRI, portable X-ray systems with built-in workstations, and Canon's lightweight Aplio me ultrasound.

Immersive visualization is emerging. Visage Imaging's Visage Ease VP brings diagnostic image review to Apple Vision Pro, and Philips' ClarifEye offers augmented reality surgical navigation.

Consolidation and partnerships are accelerating. Canon acquired NXC Imaging and partnered with Olympus on endoscopic ultrasound, reflecting the industry's push to combine capabilities quickly.

A concentrated, mature, regulated industry. A few major players dominate, innovation is incremental but steady, and stringent FDA and EMA standards make bringing new technologies to market slow and costly.

Key Global Players

The market is led by established names, including:

• GE HealthCare
• Koninklijke Philips N.V.
• Siemens Healthineers
• Canon Medical Systems Corporation
• Mindray Medical International
• FUJIFILM VisualSonics Inc.
• Carestream Health
• Hitachi
• Samsung Medison Co., Ltd.
• Koning Corporation
• PerkinElmer Inc.
• Konica Minolta
• Esaote
• Hologic, Inc.
• Varex Imaging

These companies compete through product launches, AI integration, expansion, and partnerships. Recent examples include Philips' AI-powered CT 3500 for high-volume screening and Canon's new Aquilion ONE / INSIGHT Edition and Aquilion Serve SP CT scanners.

The Road Ahead

With a projected rise from USD 45.5 billion in 2026 to USD 64.7 billion by 2033, medical imaging offers opportunity across modalities, applications, and regions. The winners will be those who pair clinical precision with AI, portability, and cost-conscious design.

Speak to Analyst to discuss how these findings apply to your strategy.

Inside the Permanent Magnets Market: Where Invisible Forces Meet Billion-Dollar Bets

Permanent magnets are the quiet workhorses of the modern economy. Unlike electromagnets, they hold their magnetic field without any external power, which makes them indispensable wherever efficiency, compactness and reliability matter. They sit inside EV traction motors, direct-drive offshore wind turbines, industrial robots, MRI scanners, aerospace actuators and the earbuds in your pocket. As the world shifts toward electrification, renewable energy and automation, demand for stronger and smaller magnets keeps rising.

That growth comes with a catch. Magnet supply chains are among the most geopolitically exposed in advanced manufacturing, with refining and production heavily concentrated in a single country. Governments and manufacturers are now racing to build alternative sources, from domestic mining to recycling to rare-earth-lean designs, and the outcome will shape who wins in this market.

This post, based on Grand View Research's analysis, covers where magnets are made, who makes them, and where the market is heading.

1. Regional Landscape & Supply Chain

Asia Pacific dominates. The region held a 75.6% revenue share in 2025, with China the largest country market. It is also expected to grow at the fastest CAGR through 2033. Demand comes from EV production, wind installations and consumer electronics. China sold over 13 million EVs in 2025 alone, out of 20.7 million globally.

The concentration risk is real. China controls roughly 70% of global refining capacity. Export controls on heavy rare earths such as dysprosium and holmium in 2025 pushed up price volatility and forced several Western OEMs to cut production or rethink sourcing.

Other regions are responding with "mine-to-magnet" strategies:

• North America: The U.S. is the largest regional market, and domestic mining and processing is being rebuilt, including Mountain Pass in California. Incentives for EV manufacturing support this.
• Europe: Heavily import-dependent for rare earths, Europe is backing industrial projects, recycling and source diversification, with EV production as the main magnet consumer.
• Latin America: Brazil holds the world's second-largest rare earth reserves. The CIT SENAI ITR facility in Minas Gerais, operating since 2024-2025, is the Southern Hemisphere's first plant making sintered NdFeB magnets at pilot scale (about 100 tons a year).
• India: In January 2026, India announced plans to start domestic rare earth magnet manufacturing by 2028, backed by a USD 860 million scheme targeting 6,000 metric tons a year. The aim is to cut an 80-90% dependence on China.

Material mix: NdFeB accounts for 71.2% of the market because of its unmatched power density in EV motors and direct-drive wind turbines. SmCo is the fastest-growing material, driven by aerospace and defense needs at temperatures between 350°C and 550°C.

Want the Full Picture? The full Grand View Research report covers segment forecasts by material, application and region (2021-2033), country-level analysis for 10 countries, and profiles of the key players. Download Free Sample Report: preview the market data, trend analysis and forecasts.

2. Key Industry Participants

The market combines global specialists, regional manufacturers and engineered-solution providers. Grand View Research profiles ten companies:

• Adams Magnetic Products Co.
• Earth-Panda Advance Magnetic Material Co., Ltd.
• Arnold Magnetic Technologies
• Daido Steel Co., Ltd.
• Eclipse Magnetics Ltd.
• Electron Energy Corp.
• Goudsmit Magnetics Group
• Hangzhou Permanent Magnet Group
• Magnequench International, LLC
• Ningbo Yunsheng Co., Ltd.

Two examples show the range. Eclipse Magnetics (UK) focuses on magnetic separation, lifting and holding, using NdFeB, SmCo, ferrite and alnico. Electron Energy Corp. (U.S.) serves aerospace, defense and medical customers with SmCo and neodymium magnets, along with machining, coating and custom assemblies.

The competitive edge is moving from volume to supply security. Companies with non-China sourcing, recycling capability or rare-earth-lean designs are gaining strategic value.

3. Market Size Projections

The global permanent magnets market was valued at USD 25.9 billion in 2025 and is estimated at USD 28.0 billion in 2026. It is projected to reach USD 47.4 billion by 2033, growing at a 6.8% CAGR from 2026 to 2033.

What drives the growth:

• Electrification: NdFeB is essential to EV traction motors.
• Renewables: Renewable capacity is projected to grow by almost 4,600 GW between 2025 and 2030. Offshore wind is expected to double to 140 GW, and direct-drive turbines use hundreds of kilograms of NdFeB per megawatt.
• Efficiency regulation: Permanent magnet synchronous motors are 15-30% more efficient than induction motors.
• Automation and miniaturization: Robotics, haptics, wearables and MRI all need smaller, stronger magnets.

By application: Consumer goods and electronics led with a 26.1% share in 2025. Energy is the fastest-growing segment.

Opportunities: Rare-earth-free and "thrifting" designs, and recycling. Recycled magnets could supply up to 10% of global demand by the mid-2030s.

The Bottom Line

The permanent magnets market is on a solid growth path toward USD 47.4 billion by 2033, but the winners will be the players who secure raw material access and diversify supply.

Customize This Report: add regions, segments or data points that fit your strategy.

The Brain Health Supplements Market Has a Proof Problem (and a Plan)

Cognitive wellness has moved from a niche interest to a mainstream health priority. Aging populations, rising stress and digital overload are pushing consumers to look for nutritional support for memory, focus, mood and sleep. Here is where the market stands and where it is headed, based on Grand View Research's latest analysis.

Current Valuation and Future Projections

The global brain health supplements market was valued at USD 12.4 billion in 2025. It is estimated at USD 14.0 billion in 2026 and is projected to reach USD 31.4 billion by 2033, a CAGR of 12.2% from 2026 to 2033.

Regional picture

• North America led in 2025 with a 38.4% revenue share, supported by strong health consciousness and demand for personalized, clinically backed formulations.
• Asia Pacific is the fastest-growing region, projected at a 16.1% CAGR through 2033. China, India and Japan are the key markets, driven by preference for natural products, preventive healthcare and rising dementia prevalence.
• Europe is growing on the shift from synthetic to naturally derived supplements, with France the largest country market in 2025.

Segment highlights

• Product: Herbal extracts held the largest share (42.5%) in 2025, as consumers favor botanicals such as ginkgo, turmeric and sage. Vitamins and minerals are the fastest-growing product group.
• Form: Capsules led with a 31.3% share, while softgels are the fastest-growing format at a 14.8% CAGR.
• Application: Stress and anxiety is among the fastest-growing use cases, with a projected 14.6% CAGR.
• Channel: Pharmacies and drug stores led with a 48.8% share. Online is growing fastest, at a 14.6% CAGR, helped by subscriptions and faster delivery.

Go Deeper with the Full Report. The Grand View Research report covers segment forecasts to 2033, country-level data across 20+ regions, company profiles and competitive benchmarking. Download the Free Sample to preview the report's data and structure.

Industry Challenges and Context

What is driving demand. Mental health awareness is rising. The WHO estimates that around 280 million people live with depression, and anxiety disorders affect about 359 million. In the U.S., roughly 7.4 million people live with Alzheimer's dementia, and the biological changes can begin up to 20 years before symptoms appear. That long window fuels interest in prevention and healthy brain aging. Demand is also broadening beyond older adults to students, professionals and athletes.

The main challenge: proof. Limited clinical validation is the market's biggest restraint. Some products have been found to carry inaccurate dosages or undeclared ingredients, and overconsumption can cause adverse effects. Products with thin evidence struggle to earn lasting consumer trust.

The industry is responding with regulatory pathways and clinical research. In August 2023, Aker BioMarine received FDA new dietary ingredient status for its LYSOVETA brain health ingredient. In 2026, Dr. Goodenowe Dietary Therapeutics announced plans to take its plasmalogen-based compounds through the FDA process.

The opportunity: personalization and science. Reckitt's Neuriva Memory 3D, launched in September 2025 with clinically tested ingredients, is a good example of the shift toward targeted, evidence-based products. Grand View Research's analysts expect the strongest competitive positions to belong to companies that offer multi-benefit cognitive solutions (memory, focus, mood, stress, sleep and healthy aging) and use digital health integration to keep consumers engaged over the long term.

Prominent Industry Players

The market mixes established nutrition companies with fast-moving direct-to-consumer brands. Companies profiled in the report include:

• Nestlé Health Science
• Amway Corporation
• Reckitt Benckiser Group PLC
• NOW Foods
• Natrol LLC
• Jarrow Formulas, Inc.
• Onnit Labs, Inc. (part of Unilever)
• Quincy Bioscience, LLC
• Natural Factors Nutritional Products Ltd.
• Bayer AG

Established players bring brand trust, wide distribution and research budgets, but they carry higher compliance costs and slower development cycles. Emerging brands such as Neuriva, Mind Lab Pro, Thesis and Qualia innovate faster and lead in digital marketing and personalization, but they face limited reach and the challenge of building clinical evidence.

Recent launches show where the product pipeline is going: Bayer's Berocca Mind with Spanish sage extract (UK, November 2024), Solaray's SharpMind Memory with a clinically studied sage blend (September 2024), and Monteloeder's MINDREVIVE botanical nootropic blend (October 2024).

Investment and Business Perspective

1. Follow the evidence. Clinically substantiated ingredients and regulatory approvals are becoming the main differentiators. Companies that invest in trials and ingredient validation are better placed to command premium pricing and consumer loyalty.
2. Look at Asia Pacific. With the fastest regional growth and rising awareness in India, China and Japan, the region suits partnerships, local launches and distribution deals. DKSH's 2025 partnership to bring brain health products to Hong Kong and Macau shows the model.
3. Bet on formats and channels that are growing. Softgels, gummies and other convenient formats, along with online and subscription sales, are gaining share. Pharmacies remain important for credibility, so an omnichannel approach makes sense.
4. Target the fastest-growing needs. Stress and anxiety, sleep and recovery, and healthy aging offer room for differentiated, multi-benefit products.
5. Build for retention. Personalization and digital health tools can turn one-time buyers into long-term customers, a point the analysts stress.
6. Manage the risks. Regulatory scrutiny, claims substantiation and quality control affect brand equity. Diligence on ingredient sourcing, testing and labeling compliance is essential for investors and operators.

Speak to an Analyst to discuss how these findings apply to your strategy.

From $77.1B to $123.2B: The Adhesives And Sealants Market's Sticky Climb

Adhesives and sealants rarely get attention, but they hold together much of modern manufacturing, from car bodies and EV battery packs to corrugated boxes, kitchen cabinets, skyscraper façades and surgical devices. As industries replace welds, rivets and screws with chemical bonding, the market is entering a steady, broad-based growth phase.

Market Overview & Projections

According to Grand View Research, the global adhesives and sealants market was valued at USD 77.1 billion in 2025. It is estimated at USD 81.7 billion in 2026 and projected to reach USD 123.2 billion by 2033, a CAGR of 6.0% over 2026–2033.

Asia Pacific led in 2025 with a 36.4% revenue share, and China was the largest country market. The industry is also highly fragmented, with many small and mid-sized players competing alongside global chemical majors. That structure shapes the competitive and M&A picture discussed below.

Key Drivers & Strategic Industry Shifts

1. Construction and infrastructure demand. Residential, commercial and public infrastructure spending is the most important demand engine. Builders are swapping mechanical fasteners for adhesives and sealants that offer better durability, flexibility and structural integrity, and they use them in flooring, roofing, insulation, glazing, panel installation and waterproofing. Urbanization programs in emerging economies add to this. In Asia Pacific, the report points to India's Smart Cities Mission and PMAY, and to Indonesia's national development plan. In Europe, renovation of an aging building stock is a further tailwind.
2. Vehicle lightweighting and electrification. Automakers use structural adhesives to cut weight, improve safety and dampen vibration. The report notes that EV makers such as Tesla, BYD and NIO are using adhesives in body-in-white construction and battery assemblies, and that Henkel, 3M and Sika are scaling up in China to serve this demand.
3. The sustainability pivot. Low-VOC, water-based, solvent-free and bio-based formulations are moving from nice-to-have to necessity. Regulation and corporate sustainability targets are pushing the shift. It is also an opportunity, because bio-based chemistries are reaching applications that once needed conventional formulations, and recyclable packaging and green building add further pull.
4. Specialty and high-stakes applications. Aerospace and aviation (lightweight structural bonding, plus maintenance and repair activity), high-temperature environments, and medical uses such as surgical sealants and dental adhesives are all pushing demand toward higher-performance materials.

Headwinds to watch: Petrochemical-linked raw materials (acrylics, epoxy, polyurethane, silicones, solvents) are exposed to crude oil swings and geopolitical disruption, which squeezes margins. Tightening VOC rules also raise R&D costs and lengthen time to market.

Want the data behind this analysis? Download a Free Sample Report to see market estimates, trend analyses and forecasts across technologies, products, applications and regions.

Segment Insights

Adhesives by technology

• Reactive & others led in 2025 with a 48.7% revenue share.
• Solvent-based is forecast to be the fastest-growing technology at a 5.2% CAGR, supported by packaging, medical and tape uses.

Adhesives by product

• Acrylic led with 36.9% of revenue, thanks to its ability to bond metals, plastics, glass, ceramics and wood while resisting moisture, chemicals and UV.
• EVA is expected to grow fastest at 6.5% CAGR. It sets quickly, bonds varied substrates without water or solvents, and suits fast-paced packaging, woodworking and automotive lines.

Adhesives by application

• Paper & packaging led with 29.4%, anchored in corrugated board and carton manufacturing.
• Furniture & woodworking is the fastest-growing segment at 7.4% CAGR, driven by demand for durable, eco-friendly furniture and by hot-melt EVA, PUR and water-based systems.

Sealants by product

• Silicones led with 33.2%, including lightweighting-related automotive use.
• Acrylic sealants are the fastest growing at 6.3% CAGR, favored for their low-VOC, paintable, easy-to-apply profile in interiors.

Sealants by application

• Construction dominated with 44.8%, covering concrete joints, expansion gaps, façades and prefabricated structures.
• Packaging is growing fastest at 6.4% CAGR, as sealing solutions extend shelf life and protect against moisture, oxygen and temperature swings.

Regional snapshot: Asia Pacific leads. Latin America is expected to emerge as a high-growth region on construction and infrastructure in Brazil and Argentina. Europe is renovation-led, North America is driven by construction and automotive lightweighting, and the Middle East & Africa benefits from construction spending and automotive investment incentives, with Morocco cited as an example.

Top-Tier Competitors

The report profiles 12 companies: 3M, Ashland, Avery Dennison, H.B. Fuller, Henkel, Sika, Pidilite Industries, Huntsman, Wacker Chemie, RPM International, Dow and Kuraray.

The report splits the field into two groups:

• Established players (3M, Ashland, Avery Dennison, H.B. Fuller, Henkel, Sika, Huntsman, Wacker, RPM, Dow). Their strengths are brand recognition, broad multi-industry portfolios, strong R&D and global manufacturing and distribution. Their weaknesses are high compliance costs, raw material exposure, complex supply chains and slower commercialization. Their playbook combines capacity expansion, sustainable R&D, acquisitions and industry-specific solutions.
• Emerging players (Pidilite, Kuraray). They compete through niche and specialty technologies, bio-based chemistries and customization. They move faster and adapt more flexibly, but they have a smaller global footprint, lower bargaining power with suppliers and narrower portfolios.

For context, Henkel's portfolio includes brands such as Loctite, Teroson and Technomelt, and Dow supplies adhesive and sealant materials alongside silicones and performance materials.

The Investment & M&A Lens

A fragmented market, a 6% growth outlook and rising technical requirements make adhesives and sealants a natural consolidation arena. Recent deals and investments show where capital is going:

• H.B. Fuller / ND Industries (May 2024): The acquisition added specialty adhesives and fastener locking and sealing solutions, including the Vibra-Tite brand, plus pre-applied coating centers. It targets high-growth, high-margin segments such as automotive, electronics and aerospace.
• H.B. Fuller / Beardow Adams: The deal supports the company's European expansion, in line with regional consolidation aimed at geographic reach and portfolio depth.
• Sonoco (July 2025): A USD 30 million capacity investment aimed at packaging, automotive and industrial demand.

What this signals for investors and strategics:

1. Specialty over commodity. Engineering adhesives for electronics, EVs and aerospace command higher margins than general-purpose products.
2. Regional entry via acquisition. Buying local players is often faster than building distribution, especially in Europe and high-growth Asia Pacific and Latin America.
3. Sustainability as a valuation lever. Low-VOC and bio-based portfolios reduce regulatory risk and meet customer mandates.
4. Capacity in growth niches. Packaging, furniture and construction sealants are the fastest-growing application segments.
5. Emerging specialists as targets or partners. Niche innovators with strong polymer expertise can give larger players quicker access to new chemistries.

Key diligence risks are raw material pass-through ability, regulatory exposure by region, and customer concentration in cyclical end markets such as construction and automotive.

Final Takeaway

Adhesives and sealants are a steady compounder. Demand comes from construction, mobility, packaging and healthcare, growth is tied to lightweighting and sustainability, and a fragmented supplier base keeps consolidation active. Companies that pair specialty chemistry with regional reach are best placed to capture the next US$40+ billion of growth.

Need insights tailored to your strategy? Customize This Report: add regions, segments or data points, with 20% free customization.

The Real World Evidence Solutions Market Is Quietly Becoming Pharma's Most Valuable Asset

Clinical trials remain the gold standard for proving a therapy works, but they show only part of the picture. Real-world evidence (RWE) fills the rest by showing how treatments perform across everyday patients, settings, and timeframes. Grand View Research values the global real world evidence solutions market at USD 3.0 billion in 2025, rising to USD 3.3 billion in 2026 and USD 6.0 billion by 2033, a CAGR of 9.1%. North America led in 2025 with a 44.1% share, while Asia Pacific is expected to grow fastest.

Regulators are a big reason for this momentum. In December 2025, the U.S. FDA dropped its requirement that RWE submissions include identifiable patient-level data, so de-identified registries, claims, and EHR networks can now be considered case by case. The UK's MHRA launched an RWE Scientific Dialogue pilot in January 2025. Below, we look at what is holding the market back, what it is built on, who uses it, and who is leading it.

Systemic Challenges: The Data Problem Behind the Promise

The main obstacle is not a lack of data. Health data is growing at roughly 36% a year. The problem is that much of it is hard to use.

• Data quality and completeness. Real-world datasets often have missing values, inconsistent coding, and mixed formats across providers and countries.
• Fragmentation. Differences in clinical coding systems, disconnected EHRs, and varied care delivery practices make integration slow and costly. Combining claims and EHR data often requires heavy cleaning and normalization before the evidence is regulatory-grade.
• Regulatory scrutiny. The FDA and EMA both stress "fit-for-purpose," high-quality evidence. Poorly curated data can weaken a submission or a reimbursement case.
• Regional gaps. In Latin America, fragmented data governance and the absence of formal RWE guidelines limit progress. In the Middle East and Africa, fragmented health systems, limited local data generation, and trust in data remain hurdles, even as Saudi Arabia's SFDA advances a draft RWE framework.

The emerging fix is AI. Vendors such as IQVIA, SAS, Saama, and Veradigm are embedding AI and automation to map, clean, and standardize data, turning scattered sources into analysis-ready datasets. This is also one of the market's biggest opportunities.

Key Components & Data Sources

The market splits into two components:

1. Services (58.1% share in 2025). This is the largest segment, driven by pharma, biotech, and provider demand for outsourced RWE studies, analytics, and expertise.
2. Data sets. This segment is expected to grow at a significant rate as organizations seek to understand real-world compliance, epidemiology, and costs. It breaks down into:

• Clinical settings data (EMRs and hospital records)
• Claims data
• Pharmacy data
• Patient-powered data (patient-reported outcomes, wearables, and biometric devices)

Decentralized trials, digital therapeutics, and remote monitoring are adding longitudinal patient data, making these sources richer each year. Partnerships are also expanding access. In October 2025, HealthVerity and Claritas Rx combined de-identified claims, EMR, and lab data with specialty pharmacy and hub insights. In November 2025, Datavant and AWS launched a clean-room solution that lets life-science companies analyze multiple data sources without moving raw data.

Want the numbers behind these trends? Download a free sample of the Real World Evidence Solutions Market Report for market estimates, forecasts, and trend analysis.

Applications

• Drug development and approvals led in 2025 with a 28.7% share, as sponsors use RWE to speed development and support regulatory decisions. The FDA has also issued draft guidance on using RWD in medical device decisions.
• Medical device development and approvals.
• Reimbursement/coverage and regulatory decision-making is the fastest-growing application, as RWE frameworks for the full product lifecycle are only now being issued.
• Post-market safety and adverse event monitoring is gaining importance as therapies grow more complex. Adverse drug events are estimated to contribute to 250,000 to 300,000 deaths a year in the U.S.

Therapeutic areas

Oncology leads with about 23.1% of the market, reflecting RWE's role in lowering trial costs and improving approval odds. Cardiology is expected to grow significantly, and the market also covers neurology, diabetes, psychiatry, and respiratory care.

End users

• Healthcare companies (pharma, biopharma, and device makers) held the largest share in 2025, using RWE across clinical research, commercial, HEOR, and market access.
• Healthcare payers are the fastest-growing group. RWE already appears in around 16% of clinical findings cited by payers in specialty drug decisions, with EHR data the most cited source.
• Healthcare providers and other stakeholders round out the market.

Key Industry Players

The market is slightly fragmented. Integrated data and analytics leaders like IQVIA compete with technology and health-data firms such as Oracle and Optum, while CROs and niche data specialists add further competition. Innovation, partnership activity, and regulatory influence are all high.

Companies profiled in the report include:

• IQVIA
• Merative
• PPD Inc. (now part of Thermo Fisher)
• Parexel International Corporation
• NTT DATA, Inc.
• ICON plc
• Oracle
• Syneos Health
• Cegedim Health Data
• Medpace
• Optum Inc. (UnitedHealth Group)
• SAS Institute Inc.
• Cognizant
• Aetion (acquired by Datavant in May 2025)
• Flatiron Health
• Cytel Inc.
• Trinity

Recent moves show where competition is heading:

• Thermo Fisher launched the CoreVitas Obesity Registry in January 2026.
• Aetion listed its evidence platform on AWS Marketplace in March 2025.
• IQVIA expanded its partnership with Salesforce in April 2024.
• Parexel partnered with Palantir on AI-driven trials in April 2024.
• Atropos Health launched its Evidence Agent in October 2025, working with Stanford Health Care and Microsoft to bring RWE into clinical workflows.

The Bottom Line

RWE is moving from a supplementary tool to a core part of drug development, regulatory review, and reimbursement. The winners will be those who can turn fragmented data into trusted, regulator-ready evidence, and AI-driven integration is a big part of that.

Have questions about the market? Speak to an Analyst to discuss the findings and how they apply to your strategy.

One Blood Draw, Many Answers: The Cancer Diagnostics Market Gets Personal

Earlier detection, precision medicine, and non-invasive testing are reshaping how cancer is found, classified, and monitored. Grand View Research sizes the global cancer diagnostics market as follows:

• 2025 market size: USD 119.8 billion
• 2026 estimate: USD 126.4 billion
• 2033 forecast: USD 191.1 billion
• Growth rate: CAGR of 7.1% from 2026 to 2033

The sections below cover the macro forces behind that growth, the technologies driving it, and the companies competing for share.

Key Macro Trends Driving the Market

1. A rising global cancer burden

Cancer is the world's second leading cause of death after cardiovascular disease. The Global Burden of Disease analysis in The Lancet (September 2025) reported about 18.5 million new cases and 10.4 million cancer deaths in 2023. It projects cases will reach 30.5 million by 2050. Tobacco and alcohol use, obesity, sedentary lifestyles, poor diet, and pollution all contribute to incidence. An ageing population adds to demand for screening and diagnostic assessment.

2. The shift toward early detection

Health systems are putting more weight on catching cancer early, when outcomes are better and treatment costs are lower. Government and private investment in screening programs and diagnostic infrastructure is expanding. Japan's national screening programs, for example, reach over 94% of the population.

3. Precision oncology and personalized medicine

Treatment planning now relies on biomarker testing, molecular profiling, and genomic analysis. Companion diagnostics are paired with targeted therapies, which widens diagnostic testing across the whole cancer care pathway. Companies are also combining genomic and clinical data in molecular decision-support systems.

4. Insurance and reimbursement dynamics

Public insurance dominated the market and is expected to grow fastest as governments bring liquid biopsy, AI-driven imaging, and NGS into routine care. Private insurers such as UnitedHealthcare, Anthem, Aetna, and Cigna already cover a wide range of tests, and private cover is gaining ground in Germany, Australia, and Japan.

5. The cost barrier

High costs remain the main restraint. NGS, PET, liquid biopsy, and advanced imaging need heavy capital investment, specialized staff, and ongoing spending on reagents and maintenance. In emerging economies with limited insurance coverage, these costs slow adoption of newer technologies.

6. Regional momentum

North America led with roughly 40% of revenue in 2025, and the U.S. was the largest country market. Asia Pacific is the fastest-growing region, supported by healthcare reforms, urbanization, and rapidly ageing populations. Latin America and the Middle East & Africa are earlier-stage but promising. Many MEA markets are still largely untapped because organized screening programs are limited.

Want the full data behind this analysis? The report includes market estimates and forecasts for 2021–2033, segment-level trends, and company profiles. Download Free Sample Report

Technological Breakdown

By product: consumables lead

Consumables (antibodies, kits and reagents, probes) held 59.6% of 2025 revenue and are projected to grow fastest. Recurring use in screening, biomarker testing, and pathology sustains this segment. Instruments cover pathology systems, PCR, NGS, microarrays, and imaging. Services cover interpretation, genomic profiling, and analytics, and benefit from software-enabled platforms.

By type: IVD, LDT, and imaging

• In vitro diagnostics (IVD) led with 52.5% share. Automated systems that improve throughput and reduce errors are a key driver. The IVD technologies covered include PCR, ISH, IHC, NGS, microarrays, flow cytometry, and immunoassays.
• Laboratory-developed tests (LDTs) are expected to grow at the highest CAGR. Labs can bring them to market quickly, and they support personalized therapy decisions. Guardant Health's Shield blood test for colorectal cancer began as an LDT.
• Imaging spans MRI, CT, PET, mammography, and ultrasound. Novel imaging solutions and AI integration are improving accuracy, as with Hologic's FDA-cleared Genius Digital Diagnostics System for cervical cancer screening.

By test type: biopsy and liquid biopsy

Biopsy is estimated to grow fastest because it supports early detection, shows how aggressive a cancer is, and guides treatment selection. Liquid biopsy is a major opportunity. In May 2026, Guardant Health received FDA approval for Guardant360 Liquid CDx for comprehensive tumor profiling. In July 2024, the FDA approved Shield for colorectal cancer screening in average-risk adults aged 45 and older.

By application

Breast cancer led with 15.9% share, driven by R&D in advanced screening tools. Colorectal cancer is expected to grow fastest, spurred by demand for accurate early-detection tools.

By end use

Laboratories led with 52.1%, as hospitals increasingly rely on diagnostic labs. Home-based tests are growing quickest, at 7.16% CAGR, as payers and providers look to reduce unscheduled hospitalizations and emergency visits.

Competitive Landscape

The market has two groups of players with different strategies.

Established players include Roche, Abbott, GE HealthCare, QIAGEN, BD, Siemens Healthineers, Philips, Hologic, Thermo Fisher Scientific, and Illumina. They compete through broad portfolios across imaging, molecular diagnostics, pathology, and companion diagnostics. Their strengths are brand recognition, regulatory expertise, and global distribution. Their weaknesses are high R&D costs, complex approvals, and the constant need to keep innovating.

Emerging players include Guardant Health, Tempus AI, Caris Life Sciences, Exact Sciences, Freenome, Grail, Natera, and Haystack Oncology. They focus on liquid biopsy, MRD testing, AI-enabled diagnostics, and genomic profiling. They move fast and are strong in niche applications. Their limits are smaller global reach, dependence on external funding, and the challenge of commercializing at scale.

Recent strategic moves show where the competition is heading:

• Dec 2024: Guardant Health partnered with Boehringer Ingelheim to advance Guardant360 CDx as a companion diagnostic for zongertinib in HER2-mutant NSCLC.
• Nov 2024: Danaher announced two new Centers of Innovation in Diagnostics to advance precision medicine, including a hub in Newcastle, UK, hosted by Leica Biosystems.
• Apr 2023: Quest Diagnostics acquired Haystack Oncology to expand MRD testing.
• Feb 2023: Roche expanded its companion diagnostics collaboration with Janssen.
• Jun 2023: Blue Earth Diagnostics received FDA approval for POSLUMA, a PSMA-targeted PET imaging agent for prostate cancer.

The pattern is consistent: partnerships with pharma, acquisitions in MRD and liquid biopsy, and regional expansion. The winners are likely to combine testing technologies, data, and therapeutic partnerships into integrated oncology offerings.

The Road Ahead

Demand is structural, since cancer incidence is rising and healthcare systems are prioritizing early detection. Technology is moving toward non-invasive, genomic, and AI-enabled diagnostics. The main challenge is making these tools affordable and reimbursable outside high-income markets. Companies that solve the access problem will capture much of the growth through 2033.

Need insights tailored to your business? Add regions, segments, or competitor detail, or request a fully bespoke study. Purchase includes free customization. Customize This Report

Why Is the Augmented Reality Market Growing at Nearly 30% a Year?

AR has moved past demos and filters. Grand View Research values the global augmented reality market at USD 120.2 billion in 2025. It projects growth to USD 170.0 billion in 2026 and USD 1,050.6 billion by 2033, a 29.7% CAGR over 2026-2033. North America led in 2025 with a 34.0% revenue share, and Asia Pacific is expected to grow fastest.

This post covers four areas: the ecosystem and segments, what is driving growth, what holds it back, and where the technology is heading.

1. Core Market Ecosystem & Key Segments

The report segments the market by component, display type, application, and region.

By component

• Hardware led in 2025 with over 59% share, driven by AR headsets, smart glasses, and displays used in education, gaming, manufacturing, and aerospace & defense.
• Software is the fastest-growing component, at a CAGR above 30% through 2033. Cloud-based AR, app development platforms, and enterprise use cases such as workflow optimization and remote collaboration are pushing it.

By display

• Head-mounted displays (HMDs) led in 2025. They suit hands-free, situational-awareness work in training, simulation, defense, and manufacturing.
• Smart glasses are the fastest-growing display type. Enterprise users in logistics, manufacturing, and education value real-time data overlays and remote expert guidance, and consumers are adopting them for navigation, fitness tracking, and virtual assistants.
• The remaining display categories are head-up displays and handheld devices.

By application

• Industrial & manufacturing was the largest segment in 2025, using AR for equipment maintenance, remote assistance, and assembly-line monitoring.
• Healthcare is expected to grow fastest, through surgical visualization, medical training with 3D anatomy models, and AR-enabled telemedicine.
• Other segments are aerospace & defense, automotive, education, e-commerce & retail, and gaming & entertainment.

By region

• North America leads, backed by AR startups, heavy R&D investment, and major players.
• Europe is projected to grow at over 28% CAGR, led by Germany, France, and the UK.
• Asia Pacific is projected to grow at over 33% CAGR, driven by manufacturing scale, smartphone penetration, and government-backed AR initiatives in education and retail.

Who is shaping it: Apple (ARKit, Vision Pro) and Google (ARCore) are highlighted as key players, with Lenovo (ThinkReality) and Snap (Spectacles, AR lenses) as emerging ones. Others profiled include Meta, Magic Leap, PTC, Sony, TeamViewer, Vuzix, Wikitude, Xiaomi, Zappar, and Blippar.

Want to see the market estimates, forecasts, and trend analysis for yourself? Download Free Sample

2. Core Market Drivers & Architectural Catalysts

Better hardware and software. More processing power, better graphics, and AI integration are making AR experiences more realistic and immersive. Grand View Research names hardware and software advances as the market's primary driver.

Industry 4.0 and smart factories. AR overlays digital information on physical workspaces, which reduces downtime, cuts errors, and improves safety. That is why industrial use leads today.

Healthcare adoption. Surgical visualization, medical education, and remote diagnostics are building demand for AR in a high-stakes field.

Mobile AR. AR-capable smartphones let consumers interact with products and content in real time. Virtual try-ons, 3D mapping, and interactive gaming are now mainstream in retail and entertainment.

Cross-industry partnerships. Collaborations between AR firms and sectors such as education and retail are producing tailored solutions. The report also points to growing demand for remote assistance and collaboration tools in workflow-heavy industries.

3. Primary Operational Constraints

Note: the Grand View Research page focuses on growth factors and does not detail restraints. The points below are inferred from the report's own discussion of where hardware, adoption, and deployment still need to mature. The full report is the place to check for quantified restraint analysis.

• Hardware maturity. Long-duration comfort, battery life, and miniaturization are repeatedly cited as areas of improvement, so wearability and power still limit everyday use.
• Enterprise-first adoption. Hands-free use in industrial, defense, and healthcare settings is proven. Broad consumer adoption of smart glasses is still developing.
• Ecosystem dependence. The market leans on a few platform owners (Apple, Google, and Meta), so developers and enterprises face platform choices that shape their roadmaps.
• Integration complexity. AR value depends on tying into AI, IoT, and cloud systems, which adds implementation effort for organizations.
• Regional variability. Growth is uneven, with mature North American demand and fast-rising but differently structured Asia Pacific demand.

4. Key Technology Frontier Matrix

Optics and displays
Magic Leap and Google extended their partnership in October 2025 into a three-year agreement. It pairs Magic Leap's waveguide optics with Google's Raxium microLED displays for Android XR devices.
Where it matters most: lightweight AR glasses.

Unified XR platforms
Samsung launched the Galaxy XR headset in October 2025 as the first device on Android XR, a platform built with Google and Qualcomm.
Where it matters most: mixed reality and developer ecosystems.

On-device AI
Gemini integration in Galaxy XR enables real-time object recognition. Integration with AI and IoT systems is also making smart glasses more practical and versatile.
Where it matters most: assistants, navigation, and field work.

Processing silicon
The Snapdragon XR2+ Gen 2 processor powers multi-app mixed reality in a lighter form factor.
Where it matters most: headsets and wearables.

True AR glasses
Meta's Orion, introduced in September 2024, pairs high-resolution displays with advanced sensors so users can interact with virtual elements in their surroundings.
Where it matters most: navigation, communication, and gaming.

Cloud and creation tools
Cloud-based AR and app development platforms are driving software, the fastest-growing component, at a CAGR above 30% through 2033.
Where it matters most: retail, education, and enterprise workflows.

Spatial understanding
Google's ARCore uses motion tracking, environmental understanding, and light estimation to blend digital content with the real world. Apple's ARKit gives its devices a similar AR foundation.
Where it matters most: mobile AR and virtual try-on.

The Bottom Line

With 29.7% CAGR ahead, AR is on track to be a core computing layer. Industrial and healthcare use cases are anchoring demand now, while smart glasses, AI, and lighter optics point to the next wave of growth. For vendors, investors, and enterprise buyers, the useful question is which segment, region, and technology bet to prioritize, and that takes data beyond a summary.

Have questions about the AR market data, or want to pressure-test it against your strategy? Speak to Analyst

Inside the Enzymes Market: The Invisible Catalysts Powering a USD 25.1 Billion Future

Enzymes are the quiet workhorses of modern industry, used in food processing, detergents, animal feed, biofuels, pharmaceuticals and diagnostics. As manufacturers look for cleaner, more efficient processes, demand keeps rising. Here is what the latest Grand View Research analysis says about the enzymes market.

Market Size & Projections

• USD 14.9 billion in 2025, rising to USD 15.8 billion in 2026

The global enzymes market started from a solid base in 2025 and is already expanding into 2026. This reflects steady demand from high-volume industries such as food and beverages, detergents and animal nutrition. It also reflects the growing role of enzymes as biocatalysts that cut energy use and chemical waste in manufacturing.

• USD 25.1 billion by 2033 at a 6.9% CAGR

Over 2026-2033, the market is projected to grow by roughly USD 9 billion from the 2026 estimate. A 6.9% CAGR points to sustained, broad-based growth rather than a short-lived spike. The report describes the industry as being in a medium growth stage with the pace of expansion steadily accelerating.

• Industrial enzymes lead, specialty enzymes grow fastest

Industrial enzymes held a 56.5% revenue share in 2025 thanks to their use across food processing, detergents, textiles, pulp and paper, feed, biofuels and wastewater treatment. Specialty enzymes are projected to grow faster, at a 7.0% CAGR. They serve high-precision areas such as drug formulation, enzyme replacement therapy, PCR-based diagnostics and biocatalysis, where purity and specificity command premium demand.

• Carbohydrases dominate, proteases accelerate

Carbohydrases (including amylases, cellulases and xylanases) captured a 47.9% share in 2025. They break complex carbohydrates into simple sugars for starch conversion, juice clarification, dough conditioning and biomass saccharification. Proteases are expected to grow fastest, at 6.9% CAGR, driven by cold-water detergents, meat tenderization, cheese ripening and diagnostic uses.

• Microorganisms are the main source, plants are the fastest growing

Microbial sources accounted for 85.8% of revenue in 2025 because they are scalable, fast-growing and easy to engineer for high-yield fermentation. Plant-derived enzymes, such as bromelain and papain, are growing at 6.7% CAGR as clean-label, vegan, halal and kosher requirements push formulators toward animal-free options.

Get the Full Picture The complete report includes volume and revenue forecasts from 2018 to 2033, coverage of 19 country markets, and profiles of 10 key players. Download the Free Sample Report to preview the data, trend analysis and forecasts.

Regional Performance & Leaders

• North America: the largest market with a 36.3% share (2025)

The region's leadership rests on established enzyme manufacturers, advanced biotech infrastructure and heavy R&D investment. Demand is diversified across food processing, pharmaceuticals, animal feed, detergents and biofuels, and consumer preference for clean-label and functional foods adds momentum. Regulatory support for green technologies also helps.

• United States: the biggest country market and an innovation hub

The U.S. benefits from a mature industrial enzymes market, large healthcare biotech investment and expanding animal feed and dietary supplement industries. Close academic-industry collaboration, access to advanced fermentation technology and regulatory clarity make it easier to commercialize new enzyme products.

• Asia Pacific: the fastest-growing region at 7.9% CAGR

Rapid industrialization, rising processed food consumption and expanding healthcare infrastructure are driving the region. Tightening sustainability regulations are pushing textile, detergent and animal nutrition manufacturers toward eco-efficient enzymatic alternatives. Abundant raw materials and favorable production economics are also attracting global players to invest in local manufacturing and research.

• China: a major consumer building domestic capability

China is among the world's largest consumers of industrial and specialty enzymes, spanning food processing, pharmaceuticals and detergents. Government incentives for clean energy and bio-based industries support enzyme use in biofuels and environmental applications. Rising health awareness is also lifting demand for enzyme-based supplements and functional foods, while domestic biotech investment aims to reduce import reliance.

• Europe: sustainability-led strength

Europe holds a strong global share owing to its long-standing biopharmaceutical base, strict environmental policies and leadership in sustainable industrial practices. The EU promotes enzymes as part of green chemistry, particularly in biodegradable detergents, food processing and agricultural biotech. Bakery, dairy, brewing and feed demand drive innovation. Germany stands out for precision fermentation and industrial biotech infrastructure.

• Latin America and Middle East & Africa: emerging growth pockets

In Latin America, Brazil, Mexico and Argentina are adopting enzymes across agriculture, food and beverage, feed and ethanol production, supported by government backing for biofuels. In the Middle East and Africa, healthcare investment, expanding GCC food and beverage industries and enzyme use in agriculture and feed are creating new demand.

• Competitive leaders: Novonesis, IFF and DSM

The market is moderately concentrated, with these three shaping industry direction, especially in industrial enzymes, which require high investment and long development cycles. Other profiled players include BASF, Novus International, Associated British Foods, Kerry, Advanced Enzyme Technologies, Amano Enzyme and Adisseo. Recent milestones include the January 2024 Novozymes and Chr. Hansen merger that created Novonesis, and the March 2025 IFF-Kemira joint venture, Alpha Bio, focused on enzyme-enabled biobased materials.

Market Drivers & Core Trends

• Sustainable, low-impact manufacturing

Enzymes work under mild conditions, which lowers energy consumption and reduces chemical waste. As industries face pressure to decarbonize and cut pollution, replacing harsh chemical catalysts with enzymes has become both an environmental and a cost-saving strategy.

• Clean-label food and beverage demand

Consumers increasingly prefer natural ingredients and less processing. Enzyme-based formulations improve yield, texture, flavor and shelf life without synthetic additives. Growth in dairy, brewing and packaged foods further strengthens this driver.

• Animal nutrition

Feed enzymes improve nutrient absorption and animal health while reducing the environmental footprint of livestock production. This makes them a growing priority for producers focused on efficiency and sustainability.

• Advances in enzyme engineering

Increased R&D in recombinant DNA technology, synthetic biology and precision fermentation is enabling scalable production of high-specificity enzymes. These tools help companies tailor enzyme profiles for specific industrial, pharmaceutical and food applications.

• Pharma, diagnostics and biotech expansion

Personalized medicine, molecular research and precision diagnostics are increasing demand for high-purity specialty enzymes. Applications range from PCR and DNA modification to therapeutic enzyme replacement.

• Opportunity: plant-based and microbial alternatives

Shifting away from animal-derived enzymes reduces raw material volatility and meets ethical, halal and kosher requirements. Textiles, detergents, pulp and paper, and biofuels are also adopting enzymes to reduce chemical load.

• Challenges: raw materials, fermentation and regulation

Volatile pricing for animal-sourced inputs, contamination-sensitive fermentation, GMO-related regulation and complex regional approval processes can squeeze margins and delay launches. Companies that manage these risks well gain a competitive edge.

Customize This Report to add regions, segments or data points that fit your strategy. Purchases include free customization.

The Biosensors Market Is Quietly Heading for USD 64 Billion. Are You Paying Attention?

Biosensors have moved out of the lab and into everyday life. They sit in continuous glucose monitors, smart rings, sweat-analysis patches, and field devices that check soil health. According to Grand View Research, this shift is driving strong, sustained expansion across healthcare, agriculture, and food safety.

Market Growth & Projections

The global biosensors market was valued at USD 32.2 billion in 2025. It is estimated at USD 34.7 billion in 2026 and is projected to reach USD 64.0 billion by 2033, a CAGR of 9.1% from 2026 to 2033.

Demand rests on the diversity of medical applications, the rising burden of chronic and non-communicable diseases such as diabetes and hypertension, and the need for compact diagnostic devices. Rapid technological progress adds to this. The industry is fragmented, with new entrants arriving regularly, yet it also shows high levels of innovation, partnerships, and regional expansion.

Key Market Segmentation

The report segments the market by technology, application, end use, and region.

By technology: Electrochemical biosensors dominated in 2025 with a 71.6% revenue share, thanks to their wide use in biochemical measurement. Roche's AI-enabled continuous glucose monitoring system is a good example. Optical biosensors are expected to grow fastest through 2033, as they suit point-of-care settings that need fast, accurate results. Thermal and piezoelectric technologies complete the segmentation.

By application: The medical segment led with a 66.84% share in 2025. It covers blood glucose monitoring, cholesterol testing, pregnancy testing, drug discovery, blood gas analysis, and infectious disease detection. Agriculture is expected to post the fastest growth from 2026 to 2033, driven by precision farming, pathogen detection, nutrient monitoring, and IoT-enabled smart farming. Food toxicity, bioreactor, and environmental applications round out the picture.

By end use: Point-of-care (PoC) testing held the largest share at about 47.9% in 2025 and is also forecast to grow fastest. Research laboratories are set for significant growth as well, using biosensors for high-throughput screening, biomarker identification, and assay validation. Home healthcare diagnostics, the food industry, and security and bio-defense are the other end-use segments.

Pivotal Market Drivers & Technological Trends

Health monitoring goes proactive. Demand for fitness tracking and personalized wellness is a primary growth driver. Wearable biosensors can continuously track heart rate, sleep, and blood oxygen, and they are shifting healthcare from episodic care to early intervention.

AI and miniaturization. Advances in AI, machine learning, and smaller sensors have improved the accuracy and usefulness of wearables. Medtronic's edge AI-enabled insulin delivery systems, which fuse biosensor data for real-time dose adjustment, show what precision medicine outside the clinic can look like. Smart rings are also gaining traction for their comfort and finger-based accuracy.

Over-the-counter biosensors. Launches such as Abbott's Lingo (September 2024) and Levels' Stelo (August 2025), the first FDA-cleared glucose biosensor available in the U.S. without a prescription, are bringing continuous glucose monitoring to the general public.

Nanotechnology and printable sensors. Nanotech-based biosensors are finding uses in food analysis, imaging, and microbial monitoring. Ultra-sensitive printable biosensors are also expanding point-of-care testing.

Partnerships. Collaborations are accelerating commercialization. Examples include Dexcom and ŌURA integrating glucose data with sleep and activity metrics, and Philips and smartQare combining wearable biosensors with monitoring platforms.

Regulation. Frameworks such as HIPAA and GDPR shape how patient data from connected devices is handled, so compliance is a competitive requirement.

Want deeper data on segments, regions, and competitors? Download Free Sample to preview the report's market estimates and forecasts.

Geographic Landscape

North America led in 2025 with a 42.6% revenue share. Contributing factors include high chronic disease prevalence, strong reimbursement, rapid AI adoption in digital health, and frequent FDA clearances. The U.S. is expected to register the fastest growth rate in the forecast period.

Europe is set for significant growth on rising public and private investment and the integration of 5G into healthcare. Germany holds the largest share in the region, and the UK is supported by its healthcare infrastructure and AI investment.

Asia Pacific is the fastest-growing region. China, India, and Japan are investing heavily in biotechnology, digital health, and medical device manufacturing. In India, digital health initiatives and demand for point-of-care diagnostics are driving adoption. In Japan, an aging population is fueling demand for remote monitoring and assisted living solutions.

Latin America is growing on the back of rising diabetes, cardiovascular, and infectious disease incidence. The Middle East & Africa is expanding on higher healthcare spending, supportive policies, and adoption of advanced medical technology.

Principal Competitors

The report profiles a broad group of companies competing through product launches, partnerships, and geographic expansion:

• Abbott Laboratories
• Medtronic
• DexCom, Inc.
• F. Hoffmann-La Roche
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.
• Johnson & Johnson Services, Inc.
• DuPont
• Sensirion AG
• Metrohm AG
• Universal Biosensors, Inc.
• Lifescan
• Nix Biosensors
• Cyrcadia Health
• Biosensors International Group
• Pinnacle Technology, Inc.
• Zimmer & Peacock AS

The Bottom Line

With a projected 9.1% CAGR, biosensors are becoming a core layer of healthcare, wellness, and precision agriculture. Consumer-ready wearables, AI-driven analytics, and fast-growing point-of-care demand all point the same way, and Asia Pacific and the U.S. are the regions to watch.

Speak to Analyst to get your questions answered by the report's research team.